Cancer cells generate the precursors for DNA replication and repair differently than healthy cells. Trethera’s lead product candidate, TRE-515, exploits this difference by inhibiting the rate-limiting enzyme in the salvage pathway of nucleotide biosynthesis.
Trethera is advancing a novel, therapeutic approach for the treatment of malignancies. Trethera’s therapy is designed to be effective in certain solid tumors with underlying metabolic sensitivity to the mechanism, or in combination with other therapeutics to enhance efficacy or overcome resistance.
11601 Wilshire Boulevard
Los Angeles, CA 90025
- Trethera Corporation announces appointment of Timothy “Tim” Donahue, M.D. to the Board of Directors
- Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy
- Trethera to attend the BIO CEO & Investor Conference